At the time of writing, Bolt Biotherapeutics Inc [BOLT] stock is trading at $0.32, up 2.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BOLT shares have gain 2.52% over the last week, with a monthly amount drifted -12.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
For the past year, the stock price of Bolt Biotherapeutics Inc fluctuated between $0.29 and $0.81. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $0.32 at the most recent close of the market. An investor can expect a potential return of 212.5% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
According to Bolt Biotherapeutics Inc [NASDAQ:BOLT], the company’s sales were 3.64M for trailing twelve months, which represents an -76.83% plunge. Gross Profit Margin for this corporation currently stands at -3.58% with Operating Profit Margin at -18.71%, Pretax Profit Margin comes in at -17.41%, and Net Profit Margin reading is -17.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is -0.97 and Total Capital is -0.94. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3073 points at the first support level, and at 0.2897 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3363, and for the 2nd resistance point, it is at 0.3477.
Ratios To Look Out For
It is important to note that Bolt Biotherapeutics Inc [NASDAQ:BOLT] has a current ratio of 3.13. Further, the Quick Ratio stands at 3.13, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 3.42, the price to book ratio is 0.27.
Transactions by insiders
Recent insider trading involved Nemec Sarah, Senior VP, Finance and PAO, that happened on Jun 06 ’24 when 2500.0 shares were purchased. Senior VP, Finance and PAO, Nemec Sarah completed a deal on Dec 16 ’24 to buy 2500.0 shares. Meanwhile, President, CEO and CFO Quinn William P. bought 2500.0 shares on Jun 06 ’24.
